Find your next paid study

Jonsson Comprehensive Cancer CenterNCT07229339

~$10 – $6,250

Locally Advanced Rectal CarcinomaRectal AdenocarcinomaStage II Rectal Cancer AJCC v8+7 more

Organ Preservation for Patients With Locally Advanced Rectal Adenocarcinoma: Evaluating the Efficacy of Short Course Radiation Therapy Followed by FOLFOX or CapeOX

This phase I trial investigates how well short-course radiation therapy followed by combination chemotherapy works in treating patients with stage II-III recta…

Jonsson Comprehensive Cancer CenterNCT04703101

~$10 – $6,250

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary…

Olema Pharmaceuticals, Inc.NCT06784193

Small Intestinal Bacterial Overgrowth

Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule

We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)

Envivo Bio IncNCT06298409

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more

A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with adva…

Non-Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia+1 more

A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of…

Imugene LimitedNCT03666000

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against dis…

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+4 more

OHSU Knight Cancer InstituteNCT06784167

~$10 – $1,125

A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-00…

AMLALLMDS

TScan Therapeutics, Inc.NCT06976736

~$10 – $1,050

Phase 2

A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)

This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will co…

Small Cell Lung CancerSCLCExtensive Stage Small Cell Lung Cancer+1 more

Racially/Ethnically Diverse Families From Urban Settings

~$10 – $7,500

Hirva MamdaniNCT05903092

Multi-level Predictors of Structural Racism and Discrimination and Associations With Health and Well-being Across the Life Course in Diverse Families

Minoritized populations face mutually reinforcing levels of structural disadvantage that contribute to poor health. Despite recognition that social and economi…

University of Colorado, DenverNCT05744973

~$10 – $750

Locally Advanced Solid TumorMetastatic Solid Tumor

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 do…

Cervical CarcinomaFallopian Tube CarcinomaMalignant Solid Neoplasm+4 more

Nuvalent Inc.NCT05118789

Phase 2

Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol

The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral n…